Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Hold" by Analysts

Key Points

• Sarepta Therapeutics, Inc. has an average analyst rating of "Hold", with five sell ratings, sixteen hold ratings, and eight buy ratings among the twenty-nine brokerages covering the stock.
• The company's shares are currently priced at around $20.37, significantly lower than its one-year high of $144.22, indicating a volatile stock performance.
• Sarepta Therapeutics reported a quarterly revenue of $611.09 million, outperforming analyst expectations and showing a 68.4% increase compared to the same quarter last year.

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have earned a consensus recommendation of "Hold" from the twenty-nine brokerages that are covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $44.1667.

SRPT has been the subject of several analyst reports. Wall Street Zen raised shares of Sarepta Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. BMO Capital Markets lifted their price objective on shares of Sarepta Therapeutics from $25.00 to $50.00 and gave the stock a "market perform" rating in a report on Tuesday, July 29th. Leerink Partnrs downgraded shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. Robert W. Baird lifted their price objective on shares of Sarepta Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Finally, William Blair reaffirmed an "outperform" rating on shares of Sarepta Therapeutics in a report on Tuesday, July 29th.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Diametric Capital LP purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at about $298,000. First Trust Advisors LP increased its position in shares of Sarepta Therapeutics by 59.2% during the second quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company's stock valued at $10,731,000 after buying an additional 233,391 shares during the period. Guggenheim Capital LLC increased its position in shares of Sarepta Therapeutics by 33.5% during the second quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company's stock valued at $783,000 after buying an additional 11,497 shares during the period. Blueshift Asset Management LLC increased its position in shares of Sarepta Therapeutics by 112.1% during the second quarter. Blueshift Asset Management LLC now owns 16,207 shares of the biotechnology company's stock valued at $277,000 after buying an additional 8,566 shares during the period. Finally, Edgestream Partners L.P. increased its position in shares of Sarepta Therapeutics by 870.3% during the second quarter. Edgestream Partners L.P. now owns 82,979 shares of the biotechnology company's stock valued at $1,419,000 after buying an additional 74,427 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Up 8.3%

Shares of NASDAQ:SRPT opened at $20.37 on Thursday. The firm has a fifty day moving average price of $20.55 and a two-hundred day moving average price of $55.29. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $144.22. The company has a market cap of $1.99 billion, a price-to-earnings ratio of -23.41 and a beta of 0.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm had revenue of $611.09 million during the quarter, compared to the consensus estimate of $530.66 million. During the same period last year, the firm earned $0.07 EPS. The business's quarterly revenue was up 68.4% compared to the same quarter last year. Analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.